Association of BRENDA-metastatic recurrence score and metastasis-free survival in early breast cancer
Dr. Florian Ebner
Although the incidence of distant relapse in decreasing, 20-30% of patients with early breast cancer (EBC) die of metastasis. The BRENDA-score is a combination of biological subtype and clinical stage. A retrospective study in the state of Baden-Wuerttemberg (Germany) found that the BRENDA-score was a robust predictive tool for breast cancer metastatic recurrence within five years after an EBC diagnosis.
